AHA/ASA Journals

Designing Medically Tailored Meal Interventions: The Food as Medicine for Families (FAME-F) Factorial Randomized Clinical Trial

BACKGROUND: Medically tailored meals (MTM) have unanswered implementation questions. Providing MTM for a specific individual, ...
FLYING Magazine

Your Guide to NASA’s Artemis II Moon Mission

NASA astronauts Reid Wiseman, Victor Glover, and Christina Koch, and Canadian Space Agency (CSA) astronaut Jeremy Hansen—the ...
Novartis

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Cure Today

Iza-Bren Improves Survival in Phase 3 Triple-Negative Breast Cancer Study

A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...
BMJ

Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients ...

Introduction Reduced thrombin generation is an important component of post cardiopulmonary bypass (CPB) coagulopathy. To replenish coagulation factors and enhance thrombin generation in bleeding ...
FierceBiotech

Novo’s CagriSema tops semaglutide in ph. 3 diabetes study

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had ...
UroToday

ASCO 2024: PSMAfore: HRQoL and Pain in a Phase 3 Study of 177Lu-PSMA-617 in Taxane-Naïve Patients with mCRPC

Previously presented at ESMO 2023, 177 Lu-PSMA-617 prolonged radiographic progression-free survival versus change of androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC in PSMAfore ...
FierceBiotech

Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at an FDA approval in the indication are looking slimmer. That said, the ...
Monthly Prescribing Reference

Tolebrutinib Misses Primary Endpoint in Phase 3 PPMS Study

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...
BioSpace

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance ...
Business Wire

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary ...

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated ...